Although MAX is widely regarded as an obligate dimerization partner for MYC, its function in normal development and neoplasia is not well defined. We show that B-cell specific deletion of Max has a surprisingly modest effect on B-cell development but completely abrogates Eµ-Myc driven lymphomagenesis. In both contexts, MAX loss leads to a significant reduction in MYC protein levels.
INTRODUCTION
The MAX protein was first identified as a specific dimerization partner with members of the MYC oncoprotein family (MYC, MYCN and MYCL) . Like MYC, MAX is a member of the basic region-helixloop-helix-zipper (bHLHZ) class of transcriptional regulators, and the association of MYC with MAX is mediated by heterodimerization between their two HLHZ domains. MYC-MAX heterodimers bind DNA through direct contact of each bHLHZ basic region with the major groove of E-box DNA sequences (CANNTG) (for reviews see (Conacci-Sorrell et al. 2014 ) (Carroll et al. 2018) ). MYC does not homodimerize or bind DNA under physiological conditions and, aside from MAX, no other bHLHZ proteins have been compellingly demonstrated to dimerize with MYC. Because mutations in the MYC bHLHZ that prevent association with MAX also block MYC's major biological activities, it has been generally assumed that MAX is required for MYC function. Moreover, targeted deletion of Max in mice results in early post-implantation lethality, consistent with essential functions for Myc and MycN during embryonic development (Shen-li et al. 2000) . In addition to dimerizing with MYC family proteins, MAX also forms E-box DNA binding heterodimers with the MXD family, MNT and MGA proteins, all of which act as transcriptional repressors.
Despite the apparent centrality of MAX for the functions of multiple bHLHZ transcription factors there is evidence that MAX loss of function can be tolerated and even oncogenic in several biological contexts. For example, pheochromocytoma cell lines can proliferate in the absence of MAX and a subset of familial pheochromocytomas are strongly associated with inactivation of Max (Hopewell and Ziff 1995) (Comino-Méndez et al. 2011 ). In addition, approximately 6% of human small cell lung carcinomas (SCLC) exhibit loss of MAX, and introduction of MAX into human SCLC lines lacking MAX arrests growth (Romero et al. 2014) . Lastly, in Drosophila melanogaster larval development is less compromised by loss of MAX than by loss of MYC, and several critical activities of MYC appear unaffected by MAX inactivation (Steiger et al. 2008) . These findings suggest that there are functions of MYC independent of MAX and that loss of MAX in some settings can promote oncogenic conversion.
To investigate a MAX-independent role in MYC induced oncogenesis we turned to Eμ-Myc transgenic mice which model the 8;14 translocation found in Burkitt's B cell lymphomas and have provided many insights into MYC driven lymphomagenesis. The over-expression of MYC produces a polyclonal increase in pre-B cells in young mice, accompanied by reduced differentiation to mature B cells (Harris et al. 1988 ). Earlier work, using an Eµ-Max transgene, established that overexpression of MAX alone in murine lymphoid cells is non-oncogenic and results in reduced B-cell proliferation and numbers. Importantly, in the context of an Eµ-Myc transgene, augmented expression of Max also attenuated B cell lymphomagenesis and reduced lymphoproliferation (Lindeman et al. 1995), indicating that the ratio of MYC:MAX expression levels can influence MYC function. However, the requirement for endogenous MAX in MYC induced tumorigenesis has not been determined. To address these questions, we generated a conditional Max allele to elucidate Max function in lymphomagenesis and in B-cell homeostasis.
RESULTS AND DISCUSSION

Max deletion partially impairs B cell development
We constructed a Max targeting vector by inserting loxP sites (and a Neomycin resistance gene) flanking exon 4 within a full-length Max genomic clone. This region encodes nearly the entire helix 2-leucine zipper region of Max necessary for dimerization with MYC and other bHLHZ proteins (Fig.   1A ), and its Cre-mediated deletion is expected to lead to a frame shift and truncation within exon 5, leading to a 127aa protein lacking the HLHZ domain. Expression of Cre in Max fl/+ ES cells resulted in heterozygous deletion of Max (Max ∆/+ ) and these ES cells were employed to produce chimeric mice.
Extensive intercrossing of Max
∆/+ F1 mice failed to produce any homozygous Max null offspring, consistent with a previous report (Supplemental Fig. S1A ) (Shen-li et al. 2000) .
We next crossed Max fl/fl mice with hemizygous mb1-Cre transgenic mice. Expression of the mb1 gene is restricted to B-cells beginning at the early pro-B-cell stage and mb1-Cre has been used extensively to study B-cell development and function (Hobeika et al. 2006 pre-B-cell differentiation (Fig. 1D ). This block in development is similar to that seen upon Myc loss in B cells (Habib et al, 2007) . In addition, BM precursors from Max KO mice failed to efficiently differentiate into B220+ cells upon treatment with IL-7 in vitro (Supplemental Fig S1B, C) . We also noted a compensatory increase in the percentages of CD3+ T cells and CD11b+ myeloid cells (Supplemental Fig. S1D ). To study mature B-cell populations, we examined spleens of Max KO mice.
A majority ( ~86%) of B220+ cells lacked detectable MAX staining in their nuclei (Fig. 1E ). This correlated with reduced numbers of total splenocytes ( Fig.1F ) and CD19+ B220+ splenocytes in the Max KO spleens compared to Max WT (Fig.1G, Supplemental Fig. S1E ). Indeed, B220+ areas in the spleen displayed a significant reduction in Ki67 staining (Fig. 1H, Supplemental Fig. S1F ).
Intriguingly, loss of Ki67 appeared to be most dramatic in areas corresponding to germinal centers (GC). Since MYC is known to play a critical role in GC formation and maintenance (Calado et al. Similarly, depletion of Max in the T cell lineage using lck-cre led to marginally impaired differentiation of double negative (DN) to double positive thymocytes (DP) (Supplemental Fig. S1G ), Taken together, our data indicate that Max loss attenuates overall lymphocyte development, rather than completely abolishing it.
Requirement for Max in Activated lymphocytes and Eµ-Myc-induced lymphomagenesis
To study the requirement for Max in situations where Myc expression is elevated, we activated B220+ B-cells in vitro using bacterial lipopolysaccharides (LPS). We found activation to be severely compromised in Max KO mice, and B-cells exhibited little increase in cell size (Fig 2A) . This was accompanied by reduced cell numbers, viability and apoptosis compared to LPS-treated controls ( 
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To ascertain whether Max loss affects MYC-driven lymphomagenesis, we crossed our Max conditional allele with Eµ-Myc mice in which the Myc transgene is predominantly restricted to the B lymphoid lineage (Adams et al. 1985; Harris et al. 1988) . While all the Eµ-Myc Max WT animals developed B-cell lymphomas with a median survival of 97 days, none of the Eµ-Myc Max KO mice developed lymphoma even out to 300 days (Fig. 2E , data not shown). Pre-malignant Eµ-Myc BM Bcell precursors exhibited developmental defects, including a block at the pre-B-cell stage (Langdon et al. 1986 ). Analysis of BM populations failed to show an expansion of a pre-B-cell population in Eµ-Myc Max KO mice (Fig. 2F ). In addition, B220+ cells from Eµ-Myc Max KO mice were smaller than Eµ-Myc controls and exhibited decreased total RNA content (Supplemental Fig. S2H, I ). Augmented spleen size and splenocyte numbers are typical of Eµ-Myc induced B-cell lymphomagenesis (Harris et al., 1988 
Max loss affects E2F targets and pro-inflammatory pathways in B-cells
To determine the effects of Max loss on the transcriptional program of normal and Eµ-Myc expressing B-cells we performed RNA-seq using B220+ cells of the four genotypes described above. Strikingly, Fig S3G) . GSEA revealed that cell cycle and E2F target gene sets were enriched in the MNT-MAX and MYC-MAX bound gene populations whereas there was no significant enrichment for inflammation related genes (Fig 3F) . Therefore, the effects of Max inactivation on upregulation of inflammatory genes ( Fig 3A, Supplemental Fig S3B, C) are likely to be indirect.
Max deletion in normal B-cells doesn't completely phenocopy
When we correlated MAX occupancy with gene expression changes in Max null cells, we found that approximately half the genes downregulated in Max null cells were occupied by MAX in WT cells, while 25% of upregulated genes were directly bound by MAX (Fig. 3G) . Remarkably, 86% of MAXbound genes were not differentially expressed in Max KO B-cells including the majority of MAX bound E2F target genes. Expression of E2F1-3 and phosphorylation of Rb were also unaffected by Max loss (Supplemental Fig S3H, J) . The lack of change in expression of a majority of MAX bound genes may be due to loss of binding by both the transcriptionally activating (MYC) and repressive (MXD, MNT, MGA) heterodimerization partners of MAX and is consistent with the weak effects of MAX deletion on B-cell differentiation. Consistent with this idea, we observed that the expression of MYC and E2F
targets genes that are bound by MYC, MNT and MAX remained unchanged upon the deletion of Max (Supplemental Fig S3I) .
To determine whether the gene expression changes and decreased MYC occupancy in Max KO cells is solely due to the inability of MYC to bind DNA without MAX, we measured MYC levels in Max KO B-cells. While Myc mRNA levels where not affected by Max deletion (Fig. 3H) we observed a striking reduction in MYC protein levels in Max KO cells (Fig 3I, Supplemental Fig S3K) . This result was surprising in light of previous studies indicating that MYC is subject to negative auto-regulation in normal B-cells (Grignani et al, 1990) . Importantly, however, we found that treatment of B-cells with the proteasomal inhibitor MG132 resulted in near complete restoration of MYC levels in Max KO Bcells ( Fig 3J) . Taken together, these results strongly suggest that MAX influences MYC stability.
Phosphorylation of AKT (p-AKT) and subsequent phosphorylation of GSK3β at Ser9 is known to increase MYC stability (Cross et al, 1995; Farrell and Sears, 2014) . Because levels of both p-AKT Ser473 and p-GSK3β (Ser9) appeared to be higher in Max KO B-cells (Supplemental Fig. S3J , L), we surmise that MAX loss regulates factors independent of GSK3β-mediated regulation of MYC stability.
Max loss leads to a global down-regulation of the MYC signature in Eµ-Myc expressing B-cells
When we examined whether Max deletion in premalignant Eµ-Myc cells impacts MYC levels we observed a striking decrease in MYC protein levels and half-life ( (Fig 4E) , genes downregulated in Eµ-Myc Max KO cells revealed a significant enrichment for MYC signatures (Fig 4F) . This translated to robust differences in expression where Eµ-Myc Max KO and Max WT profiles closely resemble each other and are nearly the inverse of the Eµ-Myc Max WT (Fig. 4G ). Interrogation of a publicly available ChIP-seq dataset in B-cells (Sabo et al. 2014 ) revealed that 73% of the genes known to be bound by MYC in Eµ-Myc pre-malignant cells are differentially expressed in Eµ-Myc Max KO B220+ cells (Fig. 4H, I , Supplemental Fig S4E) . We also observed that in contrast to normal B-cells, a substantial proportion of MAX regulated inflammation related genes are directly bound by MYC (Fig. 4J) . In addition, a large fraction of MYC bound E2F targets (Kuleshov et al. 2016) (Fig. 4K) are actually down-regulated in Eu-MYC MAX KO cells. This may be due partly to the decrease in E2F1-3 expression in KO cells (Supplemental Fig. S4F ).
Together, our data reveal that Burkitt's lymphoma lines and ES cells (Gregory and Hann, 2002 , Hann and Eisenman 1984 , Cartwright et al, 2005 . The rate of MYC protein degradation is mediated by several factors that interfere with signals triggering MYC ubiquitination and proteasomal degradation (Farrell and Sears, 2014) . We noted in our RNA-seq data that genes encoding MYC stability factors, including Btrc, Cip2a and Set, are upregulated in Eµ-Myc cells, relative to normal B220+ cells, and downregulated in Eµ-Myc Max KO B-cells (Fig 5A) . Moreover, the promoters of these genes are directly bound by MYC in premalignant cells (Fig. 5B, Supplemental Fig S5A) . CIP2A and SET are inhibitors of protein phosphatase 2A (PP2A) which normally dephosphorylates the stabilizing phospho-serine 62 (S62)
within the conserved Myc Box I (MB1) phospho-degron. CIP2A and SET are often overexpressed in tumors and block PP2A activity, resulting in persistence of phospho-S62 and MYC Westermarck, 2008, Junttila et al. 2007) . BTRC functions to enhance MYC stability via ubiquitylation (Popov et al. 2010 ).
To confirm whether these genes are regulated by MYC-MAX in tumor lines, we treated Daudi and P493 human B-cell lymphoma lines (Schuhmacher et al. 2001 ) with 10058-F4 (referred to herein as Myci), a small molecule reported to inhibit MYC-MAX heterodimerization (Yin et al. 2003) . We observed a decrease in MYC protein levels, accompanied by reduced proliferation and a downregulation of the stability factors in Myci treated cells (Fig. 5C , Supplemental Fig. S5 B
-E). While
Myc RNA levels were only moderately reduced (Supplemental Fig. S5F ) MYC phospho-serine62 levels were nearly eliminated upon Myci treatment (Fig. 5D ). In addition, a time-course of MYC degradation following cycloheximide treatment in P493-6 cells revealed that MYC half-life is reduced in Myci treated cells (Supplemental Fig. S5G, H) . Similar results were obtained in colon, pancreatic and lung adenocarcinoma human tumor lines (Supplemental Fig. S6A-F) . ENCODE data shows that MAX is directly associated with the promoter-proximal regions of the Btrc, Cip2a and Set genomic loci in HCT116 cells (Supplemental Fig. S6G ). To confirm that the decrease in MYC protein levels is indeed through the loss of multiple stability factors that affect Fbw7 activity, we examined MYC levels in HCT116 colon cancer cells lacking the FBW7 ubiquitin ligase known to target MYC for degradation (Welcker et al. 2004; Yada et al. 2004 ). We found that MYC turnover in FBW7-/-HCT116 is largely unaffected by treatment with the dimerization inhibitor compared to the rapid turnover in control HCT116 cells treated with inhibitor (Fig. 5F, G) . Moreover, CIP2A levels are unchanged in FBW7 null cells upon Myci treatment whereas they decrease in Myci treated WT HCT116 cells (Fig 5E) . This Our findings suggest that specific MYC-MAX dimerization inhibitors will be doubly efficacious, targeting both MYC driven transcription and MYC protein levels. In addition, by eliminating MYC, dimerization inhibitors would suppress transcription independent functions of MYC, such as those mediated by MYC-nick (Conacci-Sorrell et al. 2010 ). This additional layer of autoregulation of MYC stability is likely to have broad mechanistic consequences during tumor initiation. Our data lends support to the notion that transcriptional upregulation of PP2A inhibitors by MYC may lead to enhanced MYC stability and function in pre-malignant settings to facilitate transformation, even in the absence of genomic alterations of Myc (Junttila and Westermarck, 2008) . It will therefore be important to closely examine the consequences of MYC inhibition in cancers where PP2A is lost and/or regulators like CIP2A and SET are over-expressed.
In summary, our data suggest that loss of Max in vivo disables MYC activity through inhibition of direct MYC association with genomic DNA and through destabilization of the MYC protein itself. We surmise that increased MYC degradation is facilitated by decreased MYC-MAX activity at the promoters of genes such as Cip2a, whose protein products normally serve to stabilize MYC by attenuating FBW7 mediated proteasomal degradation (Fig 5H) (Junttila et al. 2007) . In this scenario
MYC-MAX heterodimers drive a feed-forward circuit that reinforces high MYC expression in tumors
as diverse as B-cell lymphomas and colon adenocarcinomas. In fact, a recent study shows that MYC regulates the kinase Plk1 to maintain its stability in an aggressive form of lymphoma (Ren et al. 2018 ). 
MATERIALS AND METHODS
All mice were housed and treated according to the guidelines provided by the Fred Hutch Institutional
Animal Care and Use Committee. For Max conditional mice, clonal G418R-targeted ES cell lines were produced, and integration of the targeting vector verified by genomic PCR and Southern blotting. For B-cell developmental studies, cells harvested from bone marrow and spleen were stained with fluorochrome conjugated B-cell lineage specific markers. They were then analyzed on a BD FACS Canto II. Immunohistochemistry on mouse spleens was performed after heat-induced antigen retrieval. B-cells were sorted from bone marrow using an AutoMACS mouse B-cell isolation kit and stimulated ex vivo with LPS. Cell titer glo and caspase glo luciferase assays (Promega) were utilized to assess cell growth and apoptosis. All RNA isolation was performed using the Direct-zol RNA Miniprep kit (Zymoresearch). For RNA-seq B220+ cells were purified using B220+ microbeads (AutoMACS) from spleens of 5-6-week-old mice from all genotypes, RNA integrity assessed using Tapestation (Agilent) and libraries prepared using the TruSeq RNA Sample Prep v2 kit with 500ng input RNA. Paired-end sequencing was performed on an Illumina HiSeq 2500. Reads were aligned to mm10 mouse reference genome using STAR2 and normalized using EdgeR. Gene ontology analysis was performed using hallmark datasets on mSigDB (Subramanian et al, 2005 ; Liberzon et al, 2015) .
Heatmaps were generated using Morpheus (https://software.broadinstitute.org/morpheus). For chromatin occupancy studies, primary mouse B-cells isolated from spleens were prepared fresh or stimulated ex vivo with LPS. Cells were bound to ConA beads, then permeabilized, and incubated overnight with antibody to MYC, MAX and MNT. One million cells were used per IP and the Cleavage Under Targets and Release Using Nuclease (CUT& RUN) protocol was followed (Janssens et al, 2018) . 25x25 paired-end sequencing was performed (5-10 million reads) on an Illumina HiSeq 2500 instrument and sequences were aligned to the mm10 reference genome assembly using Bowtie2.
Peak calling employed a threshold peak calling script to differentiate signal to noise. This processing was carried out with bedtools, custom R scripts defining genome position, and the GenomicRanges R package. For MYC peak calling in WT B cells, only peaks that were identified in both WT B cells and LPS stimulated B cells were considered real to mitigate background issues. De novo enrichment for sequence specificity was determined using Homer (Heinz et al, 2010) and MEME-ChIP (Machanick and Bailey, 2011) . Genomic plots were made using ngs.plot (Shen et al, 2014) or the R package ggplot2. For qRT-PCR, 500ng-2μg of input total RNA was used and cDNA generated using the Revertaid cDNA synthesis kit (Thermo-Fisher). SYBR green and FAM based methods were used to perform qPCR on a Biorad iCycler. For western blots, cells were lysed in RIPA buffer with phosphatase and protease inhibitors. For inhibitor studies, cells were treated with the MYC inhibitor 10058-F4 for 2 days prior to harvest. Cells were treated with 5μg/μl Cycloheximide and 10μM MG132.
Daudi cells were grown in RPMI with 10% FBS and HCT116 lines were maintained in DMEM with 10% FBS. Refer to Supplemental Methods for lists of reagents used. Figure 5
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